<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200327</url>
  </required_header>
  <id_info>
    <org_study_id>AOIGCSMERRI/2016/RdT01</org_study_id>
    <nct_id>NCT03200327</nct_id>
  </id_info>
  <brief_title>Comparison of Anterior Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse</brief_title>
  <acronym>SAPPRO</acronym>
  <official_title>Comparison of Anterior Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators anticipate a reduced risk of post-operational de novo stress urinary&#xD;
      incontinence following surgery for vaginal sacrospinofixation, associated with reduced costs,&#xD;
      comparable functional and anatomical efficacy and no increase in morbidity and rate of&#xD;
      dyspareunia with the new treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of de novo problematic stress urinary incontinence, operable or not, between groups response</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>≥ 2 to question 17 of PFDI-20 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>De novo dyspareunia rate the dyspareunia between groups</measure>
    <time_frame>12 months after the initial intervention</time_frame>
    <description>≥ 2 to question 11 of the PISQ-IR questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sexual life between groups</measure>
    <time_frame>12 months after the initial intervention</time_frame>
    <description>PISQ-IR questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention for suburethral band (BSU) in de novo SUI between groups</measure>
    <time_frame>up to 12 months after the initial intervention</time_frame>
    <description>binary: yes/no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare anatomical prolapse symptoms between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>POP-Q questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare functional prolapse symptoms between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PFDI-20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare quality of life associated to pelvic floor issues between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PFIQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare general quality of life between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>SF12 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare global satisfaction between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>PGI-I questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare perioperational morbidity between groups</measure>
    <time_frame>at 6 weeks and 12 months after intervention</time_frame>
    <description>complication assessed as stage ≥2 on Clavien-Dindo classification, or according to the ICS/IUGA classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare direct and indirect costs of the 2 interventions</measure>
    <time_frame>12 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Prolapse Genital</condition>
  <arm_group>
    <arm_group_label>laparoscopic promontofixation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anterior vaginal sacrospinofixation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>promontofixation</intervention_name>
    <description>reconstruction of cystoceles using a subvesical prosthesis</description>
    <arm_group_label>laparoscopic promontofixation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sacrospinofixation</intervention_name>
    <description>Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route</description>
    <arm_group_label>Anterior vaginal sacrospinofixation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Patient must be available for 12 month follow-up&#xD;
&#xD;
          -  Patient is ≥50 and &lt;80 years old&#xD;
&#xD;
          -  Patient has pelvic prolapse stage 2 or above according to international POP-Q score,&#xD;
             concerning the anterior and apical compartments, justifying surgical treatment&#xD;
&#xD;
          -  Patients not having preoperational stress urinary incontinence or having mild stress&#xD;
             urinary incontinence not causing significant functional problems (response &lt;2 to&#xD;
             question 17 of PFDI-20 questionnaire). It is possible that patients with hidden stress&#xD;
             urinary incontinence will be recruited&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in an interventional study, or is in a period of&#xD;
             exclusion determined by a previous study&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  Patient with communication issues preventing comprehension of information and&#xD;
             administration of questionnaires&#xD;
&#xD;
          -  Pelvic prolapse not affect anterior and apical compartments, regardless of stage&#xD;
&#xD;
          -  Patient with preoperative dyspareunia (patients with mild sexual discomfort related to&#xD;
             prolapse may be included&#xD;
&#xD;
          -  Patient presents with preoperative stress urinary incontinence responsible of&#xD;
             significant functional incapacity (response ≥2 to question 17 of PFDI-20&#xD;
             questionnaire).&#xD;
&#xD;
          -  Indication for concomitant suburethral sling&#xD;
&#xD;
          -  Patient with previous history of surgery for stress urinary incontinence&#xD;
&#xD;
          -  Indication of concomitant perineorrhaphy surgery with or without myorrhaphy (in both&#xD;
             groups).&#xD;
&#xD;
          -  Contra-indication for general anesthetic&#xD;
&#xD;
          -  Current urinary infection&#xD;
&#xD;
          -  Current vaginal infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de clermont-Ferrand</name>
      <address>
        <city>clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine CAMPAGNE-LOISEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Cosson</last_name>
      <email>michel.cosson@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Cosson</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine Giraudet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HFME - Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gery Lamblin</last_name>
      <email>gery.lamblin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gery Lamblin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Beau-Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Courtieu</last_name>
      <email>c.courtieu@languedoc-mutualite.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Courtieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Cornille</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Panel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara Compan</last_name>
      <phone>04 67 33 67 33</phone>
      <email>clara.compan@me.com</email>
    </contact>
    <investigator>
      <last_name>Clara Compan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud de Tayrac, MD</last_name>
      <phone>0466686868</phone>
      <email>renaud.detayrac@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud de Tayrac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte Fatton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

